IBRX270115P00012000
IBRX Jan 15 2027 12.00 Put
optionOPRA
EODOct 15, 2026
3.30USD-10.811%(-0.40)4Vol881OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
12
Expiration
Jan 15, 2027
DTE
87d
Moneyness
ITM
Intrinsic
$3.52
IBRX 12 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | $2.47 | +0.00% | 1 | 1 |
| Nov 20, 2026 | 31d | $2.20 | -26.67% | 20 | 74 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $3.30 | -10.81% | 4 | 881 |
| Mar 19, 2027 | 150d | $4.10 | +2.24% | 3 | 43 |
| Apr 16, 2027 | 178d | $4.00 | -15.79% | 1 | 3 |
| May 21, 2027 | 213d | $4.80 | -20.00% | 1 | 6 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | — | — | 0 | 0 |
| Jan 21, 2028 | 458d | $4.98 | -4.23% | 10 | 42 |
| Mar 17, 2028 | 514d | — | — | 0 | 0 |
| Jan 19, 2029 | 822d | $6.00 | -3.54% | 2 | 2 |
IBRX Nearby Strikes · Jan 15, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 5 P | $0.29 | +3.57% | 172 | 4,922 | OTM |
| 5.5 P | $0.30 | -14.29% | 30 | 33,349 | OTM |
| 7.5 P | $0.90 | +20.00% | 121 | 22,697 | OTM |
| 9 P | $1.62 | +5.88% | 72 | 52,470 | ITM |
| 10 P | $2.06 | +1.48% | 50 | 6,506 | ITM |
| 11 P | $2.65 | -7.02% | 7 | 150 | ITM |
| 12 P | $3.30 | -10.81% | 4 | 881 | ITM |
| 13 P | $4.70 | +14.63% | 2 | 6 | ITM |
| 14 P | $4.80 | -9.60% | 20 | 24 | ITM |
| 15 P | $7.70 | +21.84% | 1 | 503 | ITM |
| 16 P | $6.94 | +1.61% | 5 | 346 | ITM |
| 17 P | $7.75 | +2.24% | 56 | 92 | ITM |
| 18 P | $8.75 | +3.06% | 8 | 18 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.